A comparison of entecavir and lamivudine for the prophylaxis of hepatitis B virus reactivation in solid tumor patients undergoing systemic cytotoxic chemotherapy

PLoS ONE

Volumn 10, Issue 6, 2015, Pages

  Chen, Wen Chi ^a,b,c   Cheng, Jin Shiung ^a   Chiang, Po Hung ^a   Tsay, Feng Woei ^a,d   Chan, Hoi Hung ^a,b   Chang, Hsueh Wen ^e   Yu, Hsien Chung ^a   Tsai, Wei Lun ^a,b   Lai, Kwok Hung ^a,b   Hsu, Ping I ^a,b  

^a KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c NATIONAL KAOHSIUNG NORMAL UNIVERSITY   (Taiwan)

^d CHENG SHIU UNIVERSITY   (Taiwan)

^e NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; TENOFOVIR DISOPROXIL; VIRUS DNA; ANTIVIRUS AGENT; GUANINE;

ADULT; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SERODIAGNOSIS; SOLID TUMOR; TREATMENT OUTCOME; VIRUS REACTIVATION; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; DEMOGRAPHY; DRUG EFFECTS; MIDDLE AGED; NEOPLASMS; PHYSIOLOGY; TREATMENT WITHDRAWAL; VIROLOGY; VIRUS ACTIVATION;

HEPATITIS B VIRUS;

ANTIVIRAL AGENTS; DEMOGRAPHY; DNA, VIRAL; FEMALE; GUANINE; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NEOPLASMS; TREATMENT OUTCOME; VIRUS ACTIVATION; WITHHOLDING TREATMENT;

EID: 84938717520     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131545     Document Type: Article

References (36)

1. Liaw YF, Chu CM (2009) Hepatitis B virus infection. Lancet 373:582-592. doi: 10.1016/S0140-6736(09)60207-5 PMID: 19217993
2. Hoofnagle JH, Dusheiko GM, Schafer DF, Jones EA, Micetich KC, Young RC, et al. (1982) Reactivation of chronic hepatitis B virus infection by cancer chemotherapy. Ann Intern Med 96:447-449. PMID: 7065560
3. Lok AS, Liang RH, Chiu EK, Wong KL, Chan TK, Todd D (1991) Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology 100:182-188. PMID: 1983820
4. Yeo W, Chan PK, Zhong S, Ho WM, Steinberg JL, Tam JS, et al. (2000) Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors. J Med Virol 62:299-307. PMID: 11055239
5. Yeo W, Johnson PJ (2006) Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology 2006; 43:209-220. PMID: 16440366
6. Yeo W, Chan HL (2013) Hepatitis B virus reactivation associated with anti-neoplastic therapy. J Gastroenterol Hepatol 28:31-37. doi: 10.1111/j.1440-1746.2012.07280.x PMID: 23020594
7. Yeo W, Mo FK, Chan SL, Leung NW, Hui P, Lam WY, et al. (2007) Hepatitis B viral load predicts survival of HCC patients undergoing systemic chemotherapy. Hepatology 45:1382-1389. PMID: 17539025
8. Yeo W, Lam KC, Zee B, Chan PS, Mo FK, Ho WM, et al. (2004) Hepatitis B reactivation in patients with hepatocellular carcinoma undergoing systemic chemotherapy. Ann Oncol 15:1661-1666. PMID: 15520068
9. Yeo W, Chan PK, Hui P, Ho WM, Lam KC, Kwan WH, et al. (2003) Hepatitis B virus reactivation in breast cancer patients receiving cytotoxic chemotherapy: a prospective study. J Med Virol 70:553-561. PMID: 12794717
10. Steinberg JL, Yeo W, Zhong S, Chan JY, Tam JS, Chan PK, et al. (2000) Hepatitis B virus reactivation in patients undergoing cytotoxic chemotherapy for solid tumours: precore/core mutations may play an important role. J Med Virol 60:249-255. PMID: 10630955
11. Yeo W, Hui EP, Chan AT, Ho WM, Lam KC, Chan PK, et al. (2005) Prevention of hepatitis B virus reactivation in patients with nasopharyngeal carcinoma with lamivudine. Am J Clin Oncol 28:379-384. PMID: 16062080
12. Ling WH, Soe PP, Pang AS, Lee SC (2013) Hepatitis B virus reactivation risk varies with different chemotherapy regimens commonly used in solid tumours. Br J Cancer 108:1931-1935. doi: 10.1038/bjc.2013.225 PMID: 23652302
13. Lau GK, Yiu HH, Fong DY, Cheng HC, Au WY, Lai LS, et al. (2003) Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology 125:1742-1749. PMID: 14724827
14. Loomba R, Rowley A, Wesley R, Liang TJ, Hoofnagle JH, Pucino F, et al. (2008) Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy. Ann Intern Med 148:519-528. PMID: 18378948
15. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 125:1714-1722. PMID: 14724824
16. Chan HL, Chui AK, Lau WY, Chan FK, Hui AY, Rao AR, et al. (2004) Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis. Clin Transplant. 18:295-300. PMID: 15142051
17. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. (2006) A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med 354:1001-1010. PMID: 16525137
18. Lai CL, Shouval D, Lok AS, Chang TT, Cheinquer H, Goodman Z, et al. (2006) Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B. N Engl J Med 354:1011-1020. PMID: 16525138
19. Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, et al. (2014) Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial. JAMA 312:2521-2530. doi: 10.1001/jama.2014.15704 PMID: 25514302
20. Chen FW, Coyle L, Jones BE, Pattullo V (2013) Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease. Liver Int 33:1203-1210. doi: 10.1111/liv.12154 PMID: 23522150
21. Li HR, Huang JJ, Guo HQ, Zhang X, Xie Y, Zhu HL, et al. (2011) Comparison of entecavir and lamivudine in preventing hepatitis B reactivation in lymphoma patients during chemotherapy. J Viral Hepat 18:877-883. doi: 10.1111/j.1365-2893.2010.01386.x PMID: 21054683
22. Kim SJ, Hsu C, Song YQ, Tay K, Hong XN, Cao J, et al. (2013) Hepatitis B virus reactivation in B-cell lymphoma patients treated with rituximab: analysis from the Asia Lymphoma Study Group. Eur J Cancer 49:3486-3496. doi: 10.1016/j.ejca.2013.07.006 PMID: 23910494
23. Liaw YF, Kao JH, Piratvisuth T, Chan HLY, Chien RN, Liu CJ, et al. (2012) Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Intern 6:531-561.
24. Tseng TC, Liu CJ, Chen CL, Wang CC, Su TH, Kuo SF, et al. (2012) Serum hepatitis B virus-DNA levels correlate with long-term adverse outcomes in spontaneous hepatitis B e antigen seroconverters. J Infect Dis 205:54-63. doi: 10.1093/infdis/jir687 PMID: 22095766
25. Hsu C, Tsou HH, Lin SJ, Wang MC, Yao M, Hwang WL, et al. (2014) Chemotherapy-induced hepatitis B reactivation in lymphoma patients with resolved HBV infection: a prospective study. Hepatology 59:2092-2100. doi: 10.1002/hep.26718 PMID: 24002804
26. Huang YH, Hsiao LT, Hong YC, Chiou TJ, Yu YB, Gau JP, et al. (2013) Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B. J Clin Oncol 31:2765-2772. doi: 10.1200/JCO.2012.48.5938 PMID: 23775967
27. Yeo W, Chan PK, Ho WM, Zee B, Lam KC, Lei KI, et al. (2004) Lamivudine for the prevention of hepatitis B virus reactivation in hepatitis B s-antigen seropositive cancer patients undergoing cytotoxic chemotherapy. J Clin Oncol 22:927-934. PMID: 14990649
28. Lau GK (2008) Hepatitis B reactivation after chemotherapy: two decades of clinical research. Hepatol Intern 2:152-162.
29. Kim IK, Kim BG, Kim W, Kim D, Kim YJ, Yoon JH, et al. (2012) Clinical prediction of failure of lamivudine prophylaxis for hepatitis B virus-infected patients undergoing cytotoxic chemotherapy for malignancy. Antimicrob Agents Chemother 56:5511-5519. doi: 10.1128/AAC.00821-12 PMID: 22890764
30. European Association For The Study Of The Liver (2012) EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 57:167-185. doi: 10.1016/j.jhep.2012.02.010 PMID: 22436845
31. Mutimer D, Pillay D, Shields P, Cane P, Ratcliffe D, Martin B, et al. (2000) Outcome of lamivudine resistant hepatitis B virus infection in the liver transplant recipient. Gut 46:107-113. PMID: 10601065
32. Kim HJ, Park JH, Park DI, Cho YK, Sohn CI, Jeon WK, et al. (2010) Rescue therapy for lamivudine-resistant chronic hepatitis B: comparison between entecavir 1.0 mg monotherapy, adefovir monotherapy and adefovir add-on lamivudine combination therapy. J Gastroenterol Hepatol 25:1374-1380. doi: 10.1111/j.1440-1746.2010.06381.x PMID: 20659226
33. van Bömmel F, de Man RA, Wedemeyer H, Deterding K, Petersen J, Buggisch P, et al. (2010) Longterm efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues. Hepatology 51:73-80. doi: 10.1002/hep.23246 PMID: 19998272
34. Hui CK, Cheung WW, Au WY, Lie AK, Zhang HY, Yueng YH, et al. (2005) Hepatitis B reactivation after withdrawal of pre-emptive lamivudine in patients with haematological malignancy on completion of cytotoxic chemotherapy. Gut 54:1597-1603. PMID: 16000641
35. Jeng WJ, Sheen IS, Chen YC, Hsu CW, Chien RN, Chu CM, et al. (2013) Off-therapy durability of response to entecavir therapy in hepatitis B e antigen-negative chronic hepatitis B patients. Hepatology 58:1888-1896. doi: 10.1002/hep.26549 PMID: 23744454
36. Perrillo RP, Gish R, Falck-Ytter YT (2015) American gastroenterological association institute technical review on prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 148:221-244. doi: 10.1053/j.gastro.2014.10.038 PMID: 25447852